A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis

The purpose of this commentary is to focus on the downside of assumption-driven simulation modeling, the potential creation of a multitude of competing models, the mathematically impossible quality adjusted life year (QALY) and the failure to observe the axioms of fundamental measurement in mapping...

Full description

Saved in:
Bibliographic Details
Main Author: Paul C. Langley
Format: article
Language:EN
Published: University of Minnesota Libraries Publishing 2021
Subjects:
Online Access:https://doaj.org/article/d7b83b07b71f43c58222455a5e18945b
Tags: Add Tag
No Tags, Be the first to tag this record!